Loading clinical trials...

Ovarian Hyperstimulation Syndrome (OHSS) Prevention With Agonist | Clinical Trials | Clareo Health

COMPLETED

Ovarian Hyperstimulation Syndrome (OHSS) Prevention With Agonist

OHSS Prevention by GnRH-agonist Triggering of Final Oocyte Maturation and Cryoperservation of All Two-pronucleate Oocytes in Women Undergoing Stimulation for IVF With Gonadotrophins and GnRH-analogues: a Prospective, Observational, Multicentric, Clinical Cohort Study

NCT00835523•University Hospital Schleswig-Holstein

View on ClinicalTrials.gov

Summary

The aim of the study is to explore the concept of GnRH-agonist triggering in combination with elective cryopreservation of all 2PN oocytes at larger scale in a pragmatic clinical setting. The question asked is: "Does GnRH-agonist triggering and cryopreservation work", in terms of efficacy and safety, when applied to a larger cohort of patients, and by a number of different centres with different clinical routines.

Eligibility

Age

18 - 39 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Indication for IVF with ICSI
•Age \< 40 years
•\< 4 failed previous IVF attempts with embryo transfer
•ovarian stimulation with GnRH-antagonist and gonadotrophins
•\>20 follicles \>11 mm in mean diameter or E2 \>4500 pg/ml on the day , on which it was planned to administer hCG
•willing to participate and able to consent
•patient has not previously received GnRH-agonist as a trigger of final oocyte maturation

Exclusion Criteria

•None

Locations (10)

IVF-Augsburg

Augsburg, Germany

Deutsche Klinik Bad Münder

Bad Münder am Deister, Germany

Department of Obestrics and Gynecology, University Bonn

Bonn, Germany

Department of Obestrics and Gynecology, University Cologne

Cologne, Germany

Interdisziplinäres Kinderwunschzentrum

Düsseldorf, Germany

University Centre for Reproductive Medicine Franken

Erlangen, Germany

Department of Obestrics and Gynecology, University Clinic of Schleswig-Holstein, Campus Luebeck

Lübeck, Germany

Department of Obestrics and Gynecology, University Magdeburg

Magdeburg, Germany

Kinderwunschpraxis

Tübingen, Germany

Department of Obestrics and Gynecology, University Wuerzburg

Würzburg, Germany

Key Dates

Start Date

May 1, 2008

Primary Completion Date

July 1, 2010

Completion Date

July 1, 2010

Last Updated

June 14, 2012

Enrollment

ACTUAL participants

Conditions

Ovarian Hyperstimulation Syndrome

Association Between Live Birth Rate and Serum Progesterone During Hormonal Replacement Therapy

NCT05588635

Ovarian Hyperstimulation SyndromeFrozen-thawed Embryo Transfers

View study

UNKNOWNNA

Ovarian Hyperstimulation Syndrome Using Calcium Infusion

NCT05198128

Ovarian Hyperstimulation Syndrome

View study

COMPLETEDPHASE2

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: June 14, 2012Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Ovarian Hyperstimulation Syndrome (OHSS) Prevention With Agonist

Inclusion Criteria

Exclusion Criteria

Association Between Live Birth Rate and Serum Progesterone During Hormonal Replacement Therapy

Ovarian Hyperstimulation Syndrome Using Calcium Infusion

Management of Ovarian Hyperstimulation Syndrome as a State of Defective Mineralocorticoid Response

Gene Expression Profile After Gonadotropin Releasing Hormone (GnRH) Agonist Trigger of Oocyte Maturation

Endometrial Receptivity After GnRH Agonist Triggering

The Effect of a Dual Trigger on Intracytoplasmic Sperm Injection (ICSI) Reproductive Outcomes